Dapsone gel in the treatment of papulopustular rosacea

Comparison of dapsone 5% Topical gel with metronidazole 0.75% efficacy in combination with oral doxycycline In papulopustular rosacea

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014010516079N1

Enrollment

Registered

2014-04-26

Start date

2013-04-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papulopustular Rosacea. Other rosacea

Interventions

Intervention 1: Topical 5% dapsone gel were administered for group D and applied on the face twice daily for 12 weeks with systemic doxycycline capsule (Sobhan Darou Co.), 100 mg/day. Mode of use and

Methylparaben

Sodium Hydroxide

and purified water.treatment and total follow up period was 12 weeks. Intervention 2: Topical 0.75% metronidazole gel were administered for group M and applied on the face twice daily for12 weeks wit

and purified water.treatment and total follow up period was 12 weeks.

Treatment - Drugs

Topical 5% dapsone gel were administered for group D and applied on the face twice daily for 12 weeks with systemic doxycycline capsule (Sobhan Darou Co.), 100 mg/day. Mode of use and application in t

Topical 0.75% metronidazole gel were administered for group M and applied on the face twice daily for12 weeks with Systemic doxycycline capsule (Sobhan Darou Co.), 100 mg/day.Mode of Use and applicat

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 18 and 55, patients with papulopustular facial rosacea, negative history of using topical steroid or retinoic acid during last month, negative history of using oral anti-inflammatory agents and oral retinoic acids during last month and last 180 days respectively Exclusion criteria: Pregnancy or lactation, any history of G6PD deficiency, any history of hypersensitivity to dapsone or metronidazole, any history of oral cotrimoxasole treatment

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Rasoacea papulopustular lesions. Timepoint: Baseline, week 4, week 8, week 12. Method of measurement: Number of inflammatory lesions, Visual analogue score (VAS.) and Investigator’s global assessment scores (IGA.).	—

Secondary

Measure	Time frame
Side effects of drug. Timepoint: Every 4 weeks. Method of measurement: clinical evaluation-laboratory test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Parastoo Khosravani

Isfahan University of Medical Sciences

p_khosravani@resident.mui.ac.ir+98 31 1625 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026